News > First EASL Nonalcoholic Fatty Liver Disease (NAFLD) Summit


First EASL Nonalcoholic Fatty Liver Disease (NAFLD) Summit


The First EASL Nonalcoholic Fatty Liver Disease (NAFLD) Summit: “Target-oriented approach to Diagnosis and Pharmacotherapy of Nonalcoholic Steatohepatitis (NASH), a dialogue between Academia and Industry” was held last week in Rome. 


ProSciento´s CEO, Dr. Marcus Hompesch, presented a work in collaboration with OWL Metabolomics, describing the latest updates on the application of a non-invasive integrated biomarker screening approach (NIBS) to facilitate enrollment in clinical trials with investigational therapeutics for NAFLD/NASH.





Download file

OWL is a trading name of
Parque Tecnológico de Bizkaia
Edificio 502 - Planta 0
48160 Derio - Bizkaia - Spain
+34 94 431 85 40

With this web OWL intends to provide users with information to better understand their health and their diagnosed illnesses. You should consult with a
qualified physician for diagnosis and for answers to your personal questions/circunstances.
Last update: 12/28/2022

With the collaboration of: